COLAB - Evaluation of New Long Acting Depot Formulations of Buprenorphine

National Drug and Alcohol Research Centre

Colab

Long acting depot Buprenorphine

-New formulations for the treatment of opioid dependence

Competitive advantage

Use of long acting drug deliver to revolutionise drug dependence treatment

- Long track record in drug treatment evaluation
- Highly skilled research staff
- Access to target treatment population

Recent research projects

- Community based implementation this is an implementation study of depot buprenorphine called Atrigel developed by Indivior. It is a monthly injection rather than daily administration. The study will run from late 2018 to 2020 and will be undertaken in drug services in New South Wales, Victoria and South Australia.
- Prison Based Implementation
  It is proposed to undertake a prison based study to look at the utility of depot for prisoners who are opioid dependent as an alternative to daily dispensing

Successful applications

- Partner with Indivior
- USA FDA approval received

Facilities and infrastructure

- Implementation design developed through National Drug and Alcohol

BaDGE™ - directing DNA delivery in the body

Our experts

- Prof. Michael Farrell, Treatment evaluation, Research Director
- Prof. Louisa Degenhardt, Epidemiologist

More information

Michael Farrell

Director National Drug and Alcohol Research Centre UNSW Sydney

T: +61 (0) 2 9385 0135
E: Michael.farrell@unsw.edu.au

新南威尔士大学火炬创新园区
Torch Innovation Precinct at UNSW